Inhibition of fusidic acid resistance through restricting conformational flexibility in domain III of EF-G
Proceedings of the National Academy of Sciences · 02.12.2025 · 122 (48)
DOI: 10.1073/pnas.2508779122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 24.11.2025. Verfasst von Alexandra Schindl und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, United Kingdom. Hauptthemen laut MEDLINE: Fusidic Acid, Peptide Elongation Factor G, Anti-Bacterial Agents, Drug Resistance, Bacterial. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UKRI | Biotechnology and Biological Sciences Research Council (BBSRC), Wellcome Trust, NIGMS NIH HHS.
Abstract (Originalsprache)
Fusidic acid (FA) is one of few remaining antibiotics active against Methicillin-resistant Staphylococcus aureus . FusB confers resistance to FA by rescuing the translocation factor Elongation Factor-G (EF-G) from FA-stalled ribosome complexes. FusB induces allosteric effects on dynamics in EF-G, causing significant changes in the conformational flexibility of domain III that result in an increase in a minor, more disordered state, overcoming the steric block induced by FA. We show that restraining flexibility in the two central β-strands of EF-G domain III prevents the FusB-induced increase in this minor state population, preventing FusB-mediated release of EF-G from the ribosome and thereby reinstating FA-induced stalling of protein synthesis. We further identify a region controlling access to the minor state population, potentially pinpointing the allosteric mechanism within domain III by which FusB acts. Our findings suggest a possible region that could be targeted for rational design of an inhibitor of FusB-mediated conformational flexibility, reinstating FA sensitivity even in the presence of FusB, which could rejuvenate the efficacy of this clinically important antibiotic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, United Kingdom.
- Astbury Centre for Structural Molecular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, United Kingdom.
- Newcastle University Biosciences Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, United Kingdom.
ORCID-Profile: Megan E Jones, Leela Ghimire, Antonio N Calabrese, Jennifer H Tomlinson
Förderung
- UKRI | Biotechnology and Biological Sciences Research Council (BBSRC)
- Wellcome Trust
- NIGMS NIH HHS
- Royal Society (The Royal Society)
Zitieren
APA
Schindl, A., Jones, M. E., Ghimire, L., Kalverda, A. P., Wildsmith, G., Calabrese, A. N., & Tomlinson, J. H. (2025). Inhibition of fusidic acid resistance through restricting conformational flexibility in domain III of EF-G. Proceedings of the National Academy of Sciences, 122(48). https://doi.org/10.1073/pnas.2508779122
Vancouver
Schindl A, Jones ME, Ghimire L, Kalverda AP, Wildsmith G, Calabrese AN, et al. Inhibition of fusidic acid resistance through restricting conformational flexibility in domain III of EF-G. Proceedings of the National Academy of Sciences. 2025;122(48). doi:10.1073/pnas.2508779122
BibTeX
@article{Schindl2025,
author = {Schindl, Alexandra and Jones, Megan E and Ghimire, Leela and Kalverda, Arnout P and Wildsmith, Gemma and Calabrese, Antonio N and Tomlinson, Jennifer H},
title = {Inhibition of fusidic acid resistance through restricting conformational flexibility in domain III of EF-G},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
volume = {122},
number = {48},
doi = {10.1073/pnas.2508779122}
}
EUVIMED